Philip Morris Pours $16 Billion into Science to Pave the Way for a Smoke‑Free World

At a recent Technovation conference in Tashkent, Dr. Tomoko Iida – who oversees scientific engagement for PMI across South Asia, Indochina, the CIS and the Middle East‑Africa – told reporters that the company has already ploughed a staggering $16 billion into research, development and the commercial rollout of products that are markedly less harmful than traditional cigarettes.

She stressed that the move isn’t a marketing gimmick but a response to hard‑won scientific evidence. "We know smoking kills," Iida said, "the data are crystal clear. So we’re reshaping the business around that reality." The aim, she added, is simple yet ambitious: a world where the majority of adult smokers have access to alternatives that drastically cut health risks.

Nicotine, she explained, often gets the short end of the stick in public debate. Yes, it’s addictive and not completely risk‑free, but it’s not the chief villain behind smoking‑related diseases. "It’s the combustion of tobacco that does the damage, not nicotine itself," Iida noted, adding a small pause for anyone still wondering why the company is so keen on keeping nicotine in the mix.

In practice, tobacco‑harm reduction means giving adult smokers options that satisfy the ritual, taste and throat hit they crave, without the toxic smoke. Iida pointed out that more than 60 % of adult smokers worldwide say they don’t intend to quit outright – a sobering statistic that makes safer alternatives all the more vital.

She highlighted the progress in places like Sweden and Japan, where the uptake of heated‑tobacco and other reduced‑risk products has already begun to show public‑health benefits. In Japan, smoking prevalence has slipped from roughly 20 % in 2014 to about half that today, a change she attributes to the steady availability, affordability and consumer education around these new products.

Of course, one size does not fit all. Iida reminded the audience that cultural, social and economic contexts differ wildly from country to country. In nations where tobacco farming underpins livelihoods, the conversation must also address alternative crops or new uses for tobacco leaf, she said, rather than just pushing cessation.

Regulators, too, have a role to play. "We need frameworks that encourage innovation while protecting public health," Iida urged, arguing that science‑based standards should guide product approval, labeling and marketing.

Consumer acceptance, she added, hinges on factors that go beyond chemistry – taste, aroma, even the ritual of lighting up. "If a product feels right, if it delivers satisfaction, people will switch," she said, smiling.

Financially, the shift is already reflected in PMI’s books: about 42 % of its net revenue now comes from these reduced‑risk offerings, and the company is targeting two‑thirds by 2030. In Japan, the figure tops 75 %, nudging PMI toward what it hopes will soon be a “non‑cigarette” identity.

Finally, Iida drew a clear line between heated‑tobacco products, which still use real tobacco leaf, and e‑vaping devices, emphasizing that the former belong to a distinct category and should be regulated accordingly.

With a clear‑cut vision and a hefty research budget, PMI says it’s ready to help usher in a smoke‑free future – and it hopes that India, along with many other markets, will join the journey very soon.